Repligen (NASDAQ:RGEN) Shares Gap Down - Here's What Happened

Key Points

• Repligen shares opened sharply lower, falling from a prior close of $180.17 to $168.34 despite quarterly results that exceeded analyst expectations.
• Third-quarter EPS reached $0.53 versus the $0.46 consensus, while revenue rose 10.9% year over year to $209.3 million. Management also raised full-year 2026 revenue guidance to $844 million-$852 million.
• Investor concerns may include a $41.2 million charge, acquisition-integration risks following the BioLife deal, and a valuation near 240 times earnings. Analysts nevertheless maintain a “Moderate Buy” consensus with a $175.71 price target.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $180.17, but opened at $168.34. Repligen shares last traded at $171.9850, with a volume of 226,902 shares trading hands.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Third-quarter earnings were $0.53 per share, exceeding the $0.46 analyst consensus and rising from $0.46 a year earlier. Revenue reached $209.3 million, topping estimates of approximately $206.7 million and increasing 10.9% year over year. Repligen Q3 earnings and revenue report
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $844 million-$852 million, implying reported growth of 14.5%-15.5%. Organic third-quarter revenue growth was reported at 12.5%, supporting the company’s outlook for continued demand in bioprocessing. Repligen third-quarter results and guidance
• Positive Sentiment: The completed BioLife acquisition expands Repligen’s cell-therapy offerings and could strengthen its position in a high-growth market, although integration and execution will remain important. BioLife acquisition announcement
• Negative Sentiment: Results included a reported $41.2 million charge, which may be weighing on investor sentiment despite the earnings and revenue beats. The charge raises questions about near-term profitability and acquisition-related costs. Repligen Q3 charge and guidance report
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful evidence of short-covering demand or bearish positioning. With a valuation near 241 times earnings, the stock may require continued strong growth to sustain investor expectations.

Analysts Set New Price Targets

RGEN has been the subject of several research analyst reports. Weiss Ratings upgraded Repligen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. UBS Group reiterated a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Wells Fargo & Company increased their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Zacks Research lowered shares of Repligen from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Finally, Canaccord Genuity Group raised their price target on shares of Repligen from $145.00 to $180.00 and gave the stock a "hold" rating in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.71.

Repligen Stock Performance

The company has a market capitalization of $9.90 billion, a PE ratio of 239.81, a PEG ratio of 3.23 and a beta of 1.08. The firm has a 50-day moving average of $177.37 and a two-hundred day moving average of $144.96. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The business had revenue of $209.31 million for the quarter, compared to analyst estimates of $206.71 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The business's quarterly revenue was up 10.9% compared to the same quarter last year. Research analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Institutional Investors Weigh In On Repligen

Hedge funds have recently modified their holdings of the company. Bank of Nova Scotia acquired a new position in Repligen in the 2nd quarter worth about $3,547,000. American Capital Management Inc. acquired a new stake in Repligen in the second quarter valued at approximately $49,262,000. Corient Private Wealth LP grew its holdings in Repligen by 420.9% in the second quarter. Corient Private Wealth LP now owns 11,319 shares of the biotechnology company's stock valued at $1,544,000 after purchasing an additional 9,146 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Repligen in the second quarter valued at approximately $1,173,000. Finally, Tidal Investments LLC increased its position in shares of Repligen by 75.2% in the second quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company's stock valued at $1,209,000 after buying an additional 3,803 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.